Journal of the Korean Society of Radiology (대한영상의학회지)

The Korean Society of Radiology (대한영상의학회)
권호 표지
DOI QR코드

DOI QR Code

Interventional Treatments for Femoropopliteal Arterial Disease and Recent Updates

대퇴슬와동맥의 인터벤션과 최신 지견

  • Minuk Kim (Department of Radiology, Seoul Metropolitan Government-Seoul National University Boramae Medical Center) ;
  • Soo Buem Cho (Department of Radiology, Ewha Womans University Seoul Hospital, College of Medicine, Ewha Womans University)
  • 김민욱 (서울특별시보라매병원 영상의학과) ;
  • 조수범 (이화여자대학교 의과대학 이대서울병원 영상의학과)
  • Received : 2021.04.02
  • Accepted : 2021.05.12
  • Published : 2021.05.01
Download PDF
⟨ Previous Next ⟩

Abstract

Peripheral arterial occlusive disease (PAOD) of the femoropopliteal artery is commonly caused by atherosclerosis. It can present with varying clinical symptoms depending on the degree of disease, ranging from intermittent claudication to critical limb ischemia and tissue loss. Therefore, appropriate and timely treatment is required to improve symptoms and salvage the affected limbs. Interventional approaches for femoropopliteal arterial disease commonly include percutaneous transluminal angioplasty, atherectomy, and stent placement. Over the years, endovascular recanalization has been widely performed for treating PAOD due to continuous developments in its techniques and availability of dedicated devices with the inherent advantage of being minimal invasive. In this review, we introduce various types of endovascular treatment methods, discuss the results of clinical research from existing literature, and illustrate the treatment procedures using representative images.

대퇴슬와동맥의 말초동맥폐쇄질환은 일반적으로 죽상경화증에 의해 발생하며, 질병의 정도에 따라 간헐적 파행에서부터 심각한 사지 허혈 또는 조직 손상에 이르는 다양한 증상으로 나타날 수 있다. 따라서, 증상을 개선하고 사지를 형태적, 기능적으로 보존하기 위해서는 적절한 치료가 필요하다. 대퇴슬와동맥 질환에서 시행되는 대표적인 인터벤션 치료로는 혈관 성형술, 스텐트 삽입술, 죽종절제술 등이 있다. 수년에 걸쳐, 혈관 내 재개통술은 최소 침습적이라는 이점과 더불어 시술 방법 및 사용 기기의 지속적인 발전을 토대로 말초동맥폐쇄질환의 치료에 널리 시행되고 있다. 이번 종설에서는 대퇴슬와동맥 질환의 다양한 혈관 내 치료 방법에 대해 소개하고, 문헌 고찰을 통해 현재까지 나온 임상 연구의 결과들을 논의하며, 대퇴슬와동맥질환의 치료에 적용되는 시술 방법에 대한 영상을 제시하여 독자의 이해를 돕고자 한다.

Keywords

Acknowledgement

We would like to thank Dr. Hye Jin Baek for the useful comments on the manuscript and careful reading of the manuscript.

References

  1. Song P, Rudan D, Zhu Y, Fowkes FJI, Rahimi K, Fowkes FGR, et al. Global, regional, and national prevalence and risk factors for peripheral artery disease in 2015: an updated systematic review and analysis. Lancet Glob Health 2019;7:e1020-e1030  https://doi.org/10.1016/S2214-109X(19)30255-4
  2. Mohler ER 3rd. Peripheral arterial disease: identification and implications. Arch Intern Med 2003;163:2306-2314  https://doi.org/10.1001/archinte.163.19.2306
  3. Gerhard-Herman MD, Gornik HL, Barrett C, Barshes NR, Corriere MA, Drachman DE, et al. 2016 AHA/ACC guideline on the management of patients with lower extremity peripheral artery disease: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. Circulation 2017;135:e726-e779  https://doi.org/10.1161/CIR.0000000000000502
  4. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG, et al. Inter-society consensus for the management of peripheral arterial disease (TASC II). Eur J Vasc Endovasc Surg 2007;33 Suppl 1:S1-S75  https://doi.org/10.1016/j.ejvs.2006.09.024
  5. Jaff MR, White CJ, Hiatt WR, Fowkes GR, Dormandy J, Razavi M, et al. An update on methods for revascularization and expansion of the TASC lesion classification to include below-the-knee arteries: a supplement to the Inter-Society Consensus for the management of peripheral arterial disease (TASC II). Ann Vasc Dis 2015;8:343-357  https://doi.org/10.3400/avd.tasc.15-01000
  6. Aboyans V, Ricco JB, Bartelink MEL, Bjorck M, Brodmann M, Cohnert T, et al. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed by: the European Stroke Organization (ESO) The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J 2018;39:763-816  https://doi.org/10.1093/eurheartj/ehx095
  7. European Stroke Organisation, Tendera M, Aboyans V, Bartelink ML, Baumgartner I, Clement D, et al. ESC guidelines on the diagnosis and treatment of peripheral artery diseases: document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). Eur Heart J 2011;32:2851-2906  https://doi.org/10.1093/eurheartj/ehr211
  8. Caradu C, Lakhlifi E, Colacchio EC, Midy D, Berard X, Poirier M, et al. Systematic review and updated meta-analysis of the use of drug-coated balloon angioplasty versus plain old balloon angioplasty for femoropopliteal arterial disease. J Vasc Surg 2019;70:981-995.e10  https://doi.org/10.1016/j.jvs.2019.01.080
  9. Schneider PA, Laird JR, Tepe G, Brodmann M, Zeller T, Scheinert D, et al. Treatment effect of drug-coated balloons is durable to 3 years in the femoropopliteal arteries: long-term results of the IN. PACT SFA randomized trial. Circ Cardiovasc Interv 2018;11:e005891 
  10. Laird JA, Schneider PA, Jaff MR, Brodmann M, Zeller T, Metzger DC, et al. Long-term clinical effectiveness of a drug-coated balloon for the treatment of femoropopliteal lesions. Circ Cardiovasc Interv 2019;12:e007702 
  11. Xu Y, Liu J, Zhang J, Zhuang B, Jia X, Fu W, et al. Long-term safety and efficacy of angioplasty of femoropopliteal artery disease with drug-coated balloons from the AcoArt I trial. J Vasc Surg 2021 Feb [Epub]. https://doi.org/10.1016/j.jvs.2021.01.041 
  12. Hewes RC, White RI Jr, Murray RR, Kaufman SL, Chang R, Kadir S, et al. Long-term results of superficial femoral artery angioplasty. AJR Am J Roentgenol 1986;146:1025-1029  https://doi.org/10.2214/ajr.146.5.1025
  13. Lu CT, Zarins CK, Yang CF, Sottiurai V. Long-segment arterial occlusion: percutaneous transluminal angioplasty. AJR Am J Roentgenol 1982;138:119-122  https://doi.org/10.2214/ajr.138.1.119
  14. Micari A, Vadala G, Castriota F, Liso A, Grattoni C, Russo P, et al. 1-year results of paclitaxel-coated balloons for long femoropopliteal artery disease: evidence from the SFA-Long study. JACC Cardiovasc Interv 2016;9:950-956  https://doi.org/10.1016/j.jcin.2016.02.014
  15. Micari A, Nerla R, Vadala G, Castriota F, Grattoni C, Liso A, et al. 2-year results of paclitaxel-coated balloons for long femoropopliteal artery disease: evidence from the SFA-Long study. JACC Cardiovasc Interv 2017;10:728-734  https://doi.org/10.1016/j.jcin.2017.01.028
  16. Hunink MG, Wong JB, Donaldson MC, Meyerovitz MF, Harrington DP. Patency results of percutaneous and surgical revascularization for femoropopliteal arterial disease. Med Decis Making 1994;14:71-81  https://doi.org/10.1177/0272989X9401400109
  17. Muradin GS, Bosch JL, Stijnen T, Hunink MG. Balloon dilation and stent implantation for treatment of femoropopliteal arterial disease: meta-analysis. Radiology 2001;221:137-145  https://doi.org/10.1148/radiol.2211010039
  18. Sapoval MR, Long AL, Raynaud AC, Beyssen BM, Fiessinger JN, Gaux JC. Femoropopliteal stent placement: long-term results. Radiology 1992;184:833-839  https://doi.org/10.1148/radiology.184.3.1509075
  19. Laird JR, Katzen BT, Scheinert D, Lammer J, Carpenter J, Buchbinder M, et al. Nitinol stent implantation versus balloon angioplasty for lesions in the superficial femoral artery and proximal popliteal artery: twelvemonth results from the RESILIENT randomized trial. Circ Cardiovasc Interv 2010;3:267-276  https://doi.org/10.1161/CIRCINTERVENTIONS.109.903468
  20. Kawamura Y, Ishii H, Aoyama T, Tanaka M, Takahashi H, Kumada Y, et al. Nitinol stenting improves primary patency of the superficial femoral artery after percutaneous transluminal angioplasty in hemodialysis patients: a propensity-matched analysis. J Vasc Surg 2009;50:1057-1062  https://doi.org/10.1016/j.jvs.2009.07.017
  21. Cejna M, Thurnher S, Illiasch H, Horvath W, Waldenberger P, Hornik K, et al. PTA versus Palmaz stent placement in femoropopliteal artery obstructions: a multicenter prospective randomized study. J Vasc Interv Radiol 2001;12:23-31  https://doi.org/10.1016/S1051-0443(07)61397-9
  22. Grimm J, Muller-Hulsbeck S, Jahnke T, Hilbert C, Brossmann J, Heller M. Randomized study to compare PTA alone versus PTA with Palmaz stent placement for femoropopliteal lesions. J Vasc Interv Radiol 2001;12:935-942  https://doi.org/10.1016/S1051-0443(07)61572-3
  23. Martin EC, Katzen BT, Benenati JF, Diethrich EB, Dorros G, Graor RA, et al. Multicenter trial of the wallstent in the iliac and femoral arteries. J Vasc Interv Radiol 1995;6:843-849  https://doi.org/10.1016/S1051-0443(95)71198-8
  24. Sabeti S, Schillinger M, Amighi J, Sherif C, Mlekusch W, Ahmadi R, et al. Primary patency of femoropopliteal arteries treated with nitinol versus stainless steel self-expanding stents: propensity score-adjusted analysis. Radiology 2004;232:516-521  https://doi.org/10.1148/radiol.2322031345
  25. Mewissen MW. Self-expanding nitinol stents in the femoropopliteal segment: technique and mid-term results. Tech Vasc Interv Radiol 2004;7:2-5  https://doi.org/10.1053/j.tvir.2004.01.007
  26. Schillinger M, Sabeti S, Loewe C, Dick P, Amighi J, Mlekusch W, et al. Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N Engl J Med 2006;354:1879-1888  https://doi.org/10.1056/NEJMoa051303
  27. Schillinger M, Sabeti S, Dick P, Amighi J, Mlekusch W, Schlager O, et al. Sustained benefit at 2 years of primary femoropopliteal stenting compared with balloon angioplasty with optional stenting. Circulation 2007;115:2745-2749  https://doi.org/10.1161/CIRCULATIONAHA.107.688341
  28. Dick P, Wallner H, Sabeti S, Loewe C, Mlekusch W, Lammer J, et al. Balloon angioplasty versus stenting with nitinol stents in intermediate length superficial femoral artery lesions. Catheter Cardiovasc Interv 2009;74:1090-1095  https://doi.org/10.1002/ccd.22128
  29. Duda SH, Bosiers M, Lammer J, Scheinert D, Zeller T, Oliva V, et al. Drug-eluting and bare nitinol stents for the treatment of atherosclerotic lesions in the superficial femoral artery: long-term results from the SIROCCO trial. J Endovasc Ther 2006;13:701-710  https://doi.org/10.1583/05-1704.1
  30. Dake MD, Ansel GM, Jaff MR, Ohki T, Saxon RR, Smouse HB, et al. Paclitaxel-eluting stents show superiority to balloon angioplasty and bare metal stents in femoropopliteal disease: twelve-month Zilver PTX randomized study results. Circ Cardiovasc Interv 2011;4:495-504  https://doi.org/10.1161/CIRCINTERVENTIONS.111.962324
  31. Dake MD, Ansel GM, Jaff MR, Ohki T, Saxon RR, Smouse HB, et al. Durable clinical effectiveness with paclitaxel-eluting stents in the femoropopliteal artery: 5-year results of the Zilver PTX randomized trial. Circulation 2016;133:1472-1483; discussion 1483  https://doi.org/10.1161/CIRCULATIONAHA.115.016900
  32. Muller-Hulsbeck S, Keirse K, Zeller T, Schroe H, Diaz-Cartelle J. Twelve-month results from the MAJESTIC trial of the Eluvia paclitaxel-eluting stent for treatment of obstructive femoropopliteal disease. J Endovasc Ther 2016;23:701-707  https://doi.org/10.1177/1526602816650206
  33. Muller-Hulsbeck S, Keirse K, Zeller T, Schroe H, Diaz-Cartelle J. Long-term results from the MAJESTIC trial of the Eluvia paclitaxel-eluting stent for femoropopliteal treatment: 3-year follow-up. Cardiovasc Intervent Radiol 2017;40:1832-1838  https://doi.org/10.1007/s00270-017-1771-5
  34. Golzar J, Soga Y, Babaev A, Iida O, Kawasaki D, Bachinsky W, et al. Effectiveness and safety of a paclitaxeleluting stent for superficial femoral artery lesions up to 190 mm: one-year outcomes of the single-arm IMPERIAL long lesion substudy of the eluvia drug-eluting stent. J Endovasc Ther 2020;27:296-303  https://doi.org/10.1177/1526602820901723
  35. Gray WA, Keirse K, Soga Y, Benko A, Babaev A, Yokoi Y, et al. A polymer-coated, paclitaxel-eluting stent (Eluvia) versus a polymer-free, paclitaxel-coated stent (Zilver PTX) for endovascular femoropopliteal intervention (IMPERIAL): a randomised, non-inferiority trial. Lancet 2018;392:1541-1551  https://doi.org/10.1016/S0140-6736(18)32262-1
  36. Muller-Hulsbeck S, Benko A, Soga Y, Fujihara M, Iida O, Babaev A, et al. Two-year efficacy and safety results from the IMPERIAL randomized study of the eluvia polymer-coated drug-eluting stent and the zilver PTX polymer-free drug-coated stent. Cardiovasc Intervent Radiol 2021;44:368-375  https://doi.org/10.1007/s00270-020-02693-1
  37. Bausback Y, Wittig T, Schmidt A, Zeller T, Bosiers M, Peeters P, et al. Drug-eluting stent versus drug-coated balloon revascularization in patients with femoropopliteal arterial disease. J Am Coll Cardiol 2019;73:667-679  https://doi.org/10.1016/j.jacc.2018.11.039
  38. Bosiers M, Setacci C, De Donato G, Torsello G, Silveira PG, Deloose K, et al. ZILVERPASS study: ZILVER PTX stent vs bypass surgery in femoropopliteal lesions. J Endovasc Ther 2020;27:287-295  https://doi.org/10.1177/1526602820902014
  39. Bosiers M, Deloose K, Callaert J, Moreels N, Keirse K, Verbist J, et al. Results of the Protege EverFlex 200-mm-long nitinol stent (ev3) in TASC C and D femoropopliteal lesions. J Vasc Surg 2011;54:1042-1050  https://doi.org/10.1016/j.jvs.2011.03.272
  40. Lammer J, Bosiers M, Zeller T, Schillinger M, Boone E, Zaugg MJ, et al. First clinical trial of nitinol self-expanding everolimus-eluting stent implantation for peripheral arterial occlusive disease. J Vasc Surg 2011;54:394-401  https://doi.org/10.1016/j.jvs.2011.01.047
  41. Rosenfield K, Schainfeld R, Pieczek A, Haley L, Isner JM. Restenosis of endovascular stents from stent compression. J Am Coll Cardiol 1997;29:328-338  https://doi.org/10.1016/S0735-1097(96)00498-6
  42. Zeller T, Langhoff R, Rocha-Singh KJ, Jaff MR, Blessing E, Amann-Vesti B, et al. Directional atherectomy followed by a paclitaxel-coated balloon to inhibit restenosis and maintain vessel patency: twelve-month results of the DEFINITIVE AR study. Circ Cardiovasc Interv 2017;10:e004848 
  43. Katsanos K, Spiliopoulos S, Kitrou P, Krokidis M, Karnabatidis D. Risk of death following application of paclitaxel-coated balloons and stents in the femoropopliteal artery of the leg: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc 2018;7:e011245 
  44. Nordanstig J, James S, Andersson M, Andersson M, Danielsson P, Gillgren P, et al. Mortality with paclitaxelcoated devices in peripheral artery disease. N Engl J Med 2020;383:2538-2546  https://doi.org/10.1056/NEJMoa2005206
  45. FDA. August 7, 2019 UPDATE: treatment of peripheral arterial disease with paclitaxel-coated balloons and paclitaxel-eluting stents potentially associated with increased mortality. Available at. https://www.fda.gov/medical-devices/letters-health-care-providers/august-7-2019-update-treatment-peripheral-arterial-disease-paclitaxel-coated-balloons-and-paclitaxel. Assessed Aug 7, 2019 
  46. Bolia A, Miles KA, Brennan J, Bell PR. Percutaneous transluminal angioplasty of occlusions of the femoral and popliteal arteries by subintimal dissection. Cardiovasc Intervent Radiol 1990;13:357-363  https://doi.org/10.1007/BF02578675
  47. Korean Society of Interventional Radiology. Interventional radiology. 2nd ed. Seoul: Ilchokak 2014 
  48. Lee HJ, Park SW, Chang IS, Jeon HJ, Park JH. Strategies for successful percutaneous revascularization of chronic total occlusion of the femoropopliteal arteries when the antegrade passage of a guide wire fails. Korean J Radiol 2012;13:467-475  https://doi.org/10.3348/kjr.2012.13.4.467
  49. Kokkinidis DG, Katsaros I, Jonnalagadda AK, Avner SJ, Chaitidis N, Bakoyiannis C, et al. Use, safety and effectiveness of subintimal angioplasty and re-entry devices for the treatment of femoropopliteal chronic total occlusions: a systematic review of 87 studies and 4,665 patients. Cardiovasc Revasc Med 2020;21:34-45  https://doi.org/10.1016/j.carrev.2019.03.016
  50. Cotroneo AR, Pascali D, Iezzi R. Cutting balloon versus conventional balloon angioplasty in short femoropopliteal arterial stenoses. J Endovasc Ther 2008;15:283-291  https://doi.org/10.1583/08-2366.1
  51. Amighi J, Schillinger M, Dick P, Schlager O, Sabeti S, Mlekusch W, et al. De novo superficial femoropopliteal artery lesions: peripheral cutting balloon angioplasty and restenosis rates--randomized controlled trial. Radiology 2008;247:267-272  https://doi.org/10.1148/radiol.2471070749
  52. Tsujimura T, Takahara M, Iida O, Soga Y, Katsuki T, Fujihara M, et al. Clinical outcomes of polymer-free, paclitaxel-coated stents vs stent grafts in peripheral arterial disease patients with femoropopliteal artery lesions. J Vasc Surg 2021 Jan [Epub]. https://doi.org/10.1016/j.jvs.2020.12.061 
  53. Bohme T, Noory E, Brechtel K, Scheinert D, Bosiers M, Beschorner U, et al. Heparin-bonded stent-graft for the treatment of TASC II C and D femoropopliteal lesions: 36-month results of the viabahn 25 cm trial. J Endovasc Ther 2021;28:222-228  https://doi.org/10.1177/1526602820965965
  54. Pentecost MJ, Criqui MH, Dorros G, Goldstone J, Johnston KW, Martin EC, et al. Guidelines for peripheral percutaneous transluminal angioplasty of the abdominal aorta and lower extremity vessels. A statement for health professionals from a special writing group of the Councils on Cardiovascular Radiology, Arteriosclerosis, Cardio-Thoracic and Vascular Surgery, Clinical Cardiology, and Epidemiology and Prevention, the American Heart Association. Circulation 1994;89:511-531 https://doi.org/10.1161/01.CIR.89.1.511